ArticleAllergy2014
Omalizumab therapy is associated with reduced circulating basophil populations in asthmatic children.
Article in Allergy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 42 citations in OpenAlex.
- Progenitor cell-derived basophils: A novel barcoded passive degranulation assay in allergic diseases.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2023Trial
- Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcεRI-positive cells in the skin.Theranostics · 2017Trial
- Interleukin-33-activated basophils promote asthma by regulating Th2 cell entry into lung tissue.The Journal of experimental medicine · 2024Article
- The ontogenesis and heterogeneity of basophils.Discovery immunology · 2024Review
- Basophils from allergy to cancer.Frontiers in immunology · 2022Review
- Efficacy predictors of omalizumab in Chinese patients with moderate-to-severe allergic asthma: Findings from aThe World Allergy Organization journal · 2020Article
- Allergic Comorbidity in Eosinophilic Esophagitis: Mechanistic Relevance and Clinical Implications.Clinical reviews in allergy & immunology · 2019Review
- Pediatric severe asthma: a case series report and perspectives on anti-IgE treatment.BMC pediatrics · 2018Review
- The atopic march: Critical evidence and clinical relevance.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2018Review
- Omalizumab for Severe Asthma: Beyond Allergic Asthma.BioMed research international · 2018Review
- dIvergEnt: How IgE Axis Contributes to the Continuum of Allergic Asthma and Anti-IgE Therapies.International journal of molecular sciences · 2017Review
- New insights into basophil heterogeneity.Seminars in immunopathology · 2016Review
- The Immunologic Mechanisms of Eosinophilic Esophagitis.Current allergy and asthma reports · 2016Review
- Mutual Interaction of Basophils and T Cells in Chronic Inflammatory Diseases.Frontiers in immunology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Basophils have been implicated in promoting the early development of TH 2 cell responses in some murine models of TH 2 cytokine-associated inflammation. However, the specific role of basophils in allergic asthma remains an active area of research. Recent studies in animal models and human subjects suggest that IgE may regulate the homeostasis of human basophil populations. Here, we examine basophil populations in children with severe asthma before and during therapy with the IgE-directed monoclonal antibody omalizumab. Omalizumab therapy was associated with a significant reduction in circulating basophil numbers, a finding that was concurrent with improved clinical outcomes. The observation that circulating basophils are reduced following omalizumab therapy supports a mechanistic link between IgE levels and circulating basophil populations, and may provide new insights into one mechanism by which omalizumab improves asthma symptoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.